Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07532902 |
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer |
RECRUITING | PHASE1 |
| NCT07526792 |
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07506057 |
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy |
RECRUITING | PHASE2 |
| NCT07492628 |
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma |
RECRUITING | PHASE1 |
| NCT07460245 |
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07421700 |
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07416123 |
A Study of GEN1106 in Participants With Solid Tumors |
RECRUITING | PHASE1 |
| NCT07395037 |
A Study of Ward Admissions for Haematuria |
RECRUITING | |
| NCT07390617 |
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma |
RECRUITING | |
| NCT07386847 |
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer |
NOT_YET_RECRUITING |
